Ketamine induces multiple individually distinct whole-brain functional connectivity signatures
eLife · 17.04.2024 · 13
DOI: 10.7554/elife.84173 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift eLife, online erschienen am 17.04.2024. Verfasst von Flora Moujaes und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, United States. Hauptthemen laut MEDLINE: Ketamine. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIMH NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Background
Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine’s molecular mechanisms connect to its neural and behavioral effects.
Methods
We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition. 40 healthy participants received acute ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr). We quantified resting-state functional connectivity via data-driven global brain connectivity and related it to individual ketamine-induced symptom variation and cortical gene expression targets.
Results
We found that: (i) both the neural and behavioral effects of acute ketamine are multi-dimensional, reflecting robust inter-individual variability; (ii) ketamine’s data-driven principal neural gradient effect matched somatostatin (SST) and parvalbumin (PVALB) cortical gene expression patterns in humans, while the mean effect did not; and (iii) behavioral data-driven individual symptom variation mapped onto distinct neural gradients of ketamine, which were resolvable at the single-subject level.
Conclusions
These results highlight the importance of considering individual behavioral and neural variation in response to ketamine. They also have implications for the development of individually precise pharmacological biomarkers for treatment selection in psychiatry. Funding: This study was supported by NIH grants DP5OD012109-01 (A.A.), 1U01MH121766 (A.A.), R01MH112746 (J.D.M.), 5R01MH112189 (A.A.), 5R01MH108590 (A.A.), NIAAA grant 2P50AA012870-11 (A.A.); NSF NeuroNex grant 2015276 (J.D.M.); Brain and Behavior Research Foundation Young Investigator Award (A.A.); SFARI Pilot Award (J.D.M., A.A.); Heffter Research Institute (Grant No. 1–190420) (FXV, KHP); Swiss Neuromatrix Foundation (Grant No. 2016–0111) (FXV, KHP); Swiss National Science Foundation under the framework of Neuron Cofund (Grant No. 01EW1908) (KHP); Usona Institute (2015 – 2056) (FXV). Clinical trial number: NCT03842800
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale University School of Medicine, New Haven, United States.
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital for Psychiatry Zurich, Zurich, Switzerland.
- Department of Physics, Yale University, Boston, United States.
- David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States.
- Interdepartmental Neuroscience Program, Yale University, New Haven, United States.
- Department of Psychiatry, University of Zagreb, Zagreb, Croatia.
ORCID-Profile: Flora Moujaes, Jie Lisa Ji, Charles Schleifer, Brendan D Adkinson, Franz X Vollenweider, John D Murray, Katrin H Preller, Alan Anticevic
Förderung
- NIH HHS
- NIMH NIH HHS
- NIAAA NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism
- National Science Foundation
- Brain and Behavior Research Foundation
Zitieren
APA
Moujaes, F., Ji, J. L., Rahmati, M., Burt, J. B., Schleifer, C., Adkinson, B. D., Savic, A., Santamauro, N., Tamayo, Z., Diehl, C., Kolobaric, A., Flynn, M., Rieser, N., Fonteneau, C., Camarro, T., Xu, J., Cho, Y., Repovs, G., Fineberg, S. K., …, & Anticevic, A. (2024). Ketamine induces multiple individually distinct whole-brain functional connectivity signatures. eLife, 13. https://doi.org/10.7554/elife.84173
Vancouver
Moujaes F, Ji JL, Rahmati M, Burt JB, Schleifer C, Adkinson BD, et al. Ketamine induces multiple individually distinct whole-brain functional connectivity signatures. eLife. 2024;13. doi:10.7554/elife.84173
BibTeX
@article{Moujaes2024,
author = {Moujaes, Flora and Ji, Jie Lisa and Rahmati, Masih and Burt, Joshua B and Schleifer, Charles and Adkinson, Brendan D and Savic, Aleksandar and Santamauro, Nicole and Tamayo, Zailyn and Diehl, Caroline and Kolobaric, Antonija and Flynn, Morgan and Rieser, Nathalie and Fonteneau, Clara and Camarro, Terry and Xu, Junqian and Cho, Youngsun and Repovs, Grega and Fineberg, Sarah K and Morgan, Peter T and Seifritz, Erich and Vollenweider, Franz X and Krystal, John H and Murray, John D and Preller, Katrin H and Anticevic, Alan},
title = {Ketamine induces multiple individually distinct whole-brain functional connectivity signatures},
journal = {eLife},
year = {2024},
volume = {13},
doi = {10.7554/elife.84173}
}
EUVIMED